drugset / Trial / NCT00334256

Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)

NCT00334256

Non-randomizedSingle-groupOpen-labelPrevention

Summary

To study the pharmacokinetic properties, safety and viral resistance pattern of the combination of tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their newborns, with a view to prevention of mother-to-child transmission (PMTCT) of HIV-1 in Africa and Asia.

Timeline

Start
2006-10
Primary completion
2009-07
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Small molecule 300 mg
Subject emtricitabine Other / unclassified 200 mg